Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Biotechnology

Healthcare
$15.13 +0.81%

+$0.13 today

Market cap
$2.03B
Beta
1.43
P/E (TTM)
7.2
EPS (TTM)
$2.25
52W Low $7.29High $16.88

Volume 0.76M

Average 1.21M

AUPH Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Aurinia Pharmaceuticals Inc.NASDAQ: AUPH

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation declines year over year

Q2 FY2026 stock-based compensation of $2.84M fell 47.8% year over year, ahead of the -59.1% change in trailing-twelve-month stock-based compensation. Over 3 fiscal years it compounded at -23.1% a year.

Context

  • Stock-based compensation amounted to 5.2% of revenue in FY2025, down 8.3 pp from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -47.8% holds above the trailing-twelve-month pace of -59.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.84M+427.8% QoQ
Last fiscal yearDec 2025
$14.68M-53.5% YoY
LTMJun 2026
$7.89M-59.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-47.8%——
1 year-53.5%——
3-year CAGR-23.1%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
14.68M USD
Year-over-year change
-53.5%
4-year CAGR
-17.2%

Stock-Based Compensation vs competitors

How AUPH compares with its peers on the latest reported figures

  • AUPH's LTM Jun 2026 stock-based compensation of $7.89M is the 8th largest of the 10 companies compared; the peer median is $23.96M.
  • Its year-over-year change of -59.1% is the lowest of 8, against a peer median of -2.1%.
  • Stock-based compensation amounts to 2.5% of revenue for AUPH, versus a peer median of 72.0%.
AUPH Competitors Peer median
Stock-Based Compensation for AUPH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BHVNBiohaven Ltd.LTM Jun 2026$85.94M -13.0%-16.6%—
VERAVera Therapeutics, Inc.LTM Jun 2026$49.78M +71.5%+62.2%—
ALMSAlumis Inc. Common StockLTM Jun 2026$36.4M -7.4%+94.0%492.0%
TRAXFirst Tracks Biotherapeutics IncFY2025$32.3M +20.4%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$23.96M +203.5%+10.1%—
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$12.05M -2.1%-6.3%144.0%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$9.79M -31.5%+8.6%—
AUPHAurinia Pharmaceuticals Inc.LTM Jun 2026$7.89M -59.1%-23.1%2.5%
ATTOAttovia Therapeutics, Inc.FY2025$0 ——0.0%
EVMNEvommune, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding AUPH) $23.96M-2.1%+9.4%72.0%

Competitors are the stored peer set for AUPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(180.97M)(108.18M)(78.02M)5.75M287.2M
Depreciation & Amortization2.76M2.71M11.65M19.45M9.27M
Deferred Income Tax0000(176.19M)
Stock-Based Compensation31.24M32.3M45.31M31.6M14.68M
Change in Working Capital(21.63M)(6.82M)(5.61M)5.45M(8.78M)
Accounts Receivables(15.42M)1.93M(10.61M)(12.46M)(4.91M)
Inventory(5.64M)(9.07M)(15.87M)477K(6.46M)
Accounts Payables4.08M(792K)1.24M860K(1.87M)
Other Working Capital(4.65M)1.12M19.63M16.57M4.46M
Other Non-Cash Items10.9M462K(6.79M)(17.85M)9.49M
Operating Cash Flow(157.69M)(79.53M)(33.46M)44.39M135.66M
Capital Expenditures(1.5M)(292K)(718K)(281K)(252K)
Acquisitions (Net)(1.2M)0000
Purchases of Investments(438.96M)(523.99M)(523.5M)(545.83M)(526.65M)
Sales of Investments354.43M464.32M529.38M585.42M494.13M
Other Investing Activities(16.63M)(663K)(11.86M)(43K)0
Investing Cash Flow(103.87M)(60.63M)(6.71M)39.26M(32.77M)
Debt Repayment00(10.03M)(11.99M)(13.14M)
Common Stock Issued196.74M00014.95M
Common Stock Repurchased000(40.24M)(98.16M)
Dividends Paid00000
Other Financing Activities24.37M2.43M4.9M3.14M(9.76M)
Financing Cash Flow221.11M2.43M(5.13M)(49.09M)(106.11M)
Effect of Forex Changes00000
Net Change in Cash(40.45M)(137.73M)(45.3M)34.56M(3.22M)
Free Cash Flow(159.19M)(79.82M)(34.18M)44.11M135.41M

Aurinia Pharmaceuticals Inc.

NASDAQ:AUPH

Intrinsic Alpha fair value

Locked

Current Price

$15.13

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.